Biotech Values

[jq1234]

I suppose safety ultimately did VX135 in as there is dose response from 100mg to 200mg from this trial, SVR4 73 vs 83%. I don't know whether new CMO hiring implies revival of its antiviral roots, moving more aggressively with VX765 (HIV), VX787 (influenza), VX135 (HCV). I hope not. I'd rather see them moving on with CF and other orphan indications.